Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

Immunocore

Key Facts as at 30.09.2025

Company locationUK
Size in % of securities3.60%
Size of stake in company5.60%
Market capitalizationUSD 1.8 bn

Sector

Oncology

Main candidate

Kimmtrak and IMC-F106C

Main indications

Metastatic uveal melanoma

About the company

Immunocore is a biotechnology company focused on developing T cell receptor treatments for unmet medical needs in cancer, infectious diseases, and autoimmune diseases. The company was founded in 2008 and is headquartered in Oxfordshire in the UK. Immunocore are enhancing human T cell receptors to overcome the limitations of the natural immune system and current therapeutics approaches, through engineering novel bispecific drugs called ImmTAX molecules. In early 2022 their product Kimmtrak was approved for the treatment of metastatic uveal melanoma. The company has several product candidates in clinical development including IMC-F106C, which is being tested in multiple types of cancer.

Disclaimer

All comments as at December 31, 2024 or beginning of investment.

Any reference to a particular company or security does not constitute a recommendation to buy, sell, hold or directly invest in that company or security.